Last reviewed · How we verify
Rebif New Formulation + ibuprofen PRN
Rebif (interferon beta-1a) activates interferon signaling pathways to modulate immune responses and reduce inflammation in the central nervous system.
Rebif (interferon beta-1a) activates interferon signaling pathways to modulate immune responses and reduce inflammation in the central nervous system. Used for Relapsing-remitting multiple sclerosis, Secondary progressive multiple sclerosis.
At a glance
| Generic name | Rebif New Formulation + ibuprofen PRN |
|---|---|
| Sponsor | Merck KGaA, Darmstadt, Germany |
| Drug class | Interferon beta-1a |
| Target | Interferon-beta receptor (IFNAR) |
| Modality | Small molecule |
| Therapeutic area | Immunology / Neurology |
| Phase | Phase 3 |
Mechanism of action
Interferon beta-1a binds to interferon-beta receptors on immune cells, triggering JAK-STAT signaling that increases expression of anti-inflammatory genes and reduces pro-inflammatory cytokine production. This leads to decreased migration of immune cells across the blood-brain barrier and reduced demyelination in multiple sclerosis. The new formulation likely improves pharmacokinetics, tolerability, or dosing convenience compared to the original formulation.
Approved indications
- Relapsing-remitting multiple sclerosis
- Secondary progressive multiple sclerosis
Common side effects
- Injection site reactions
- Flu-like symptoms (fever, chills, myalgia)
- Headache
- Fatigue
- Depression
- Elevated liver enzymes
- Lymphopenia
Key clinical trials
- Transition to Rebif New Formulation (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: